31 results about "Cardiometabolic disease" patented technology

The invention provides novel compounds of formulae I and II:

that are monoamine oxidase-B inhibitors, which can be useful in treating obesity, diabetes, and/or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance).

The object of the invention are compositions and medical treatment methods with an inheritable, Gram-negative, strictly anaerobic and commensal bacterium of the family Christensenellaceae belonging to an OTU (Operational Taxonomic Unit) characterized by a 16S rRNA sequence SEQ ID NO: 1 or to an OTU characterized by a165 rRNA sequence SEQ ID NO: 2.

Disclosed are compounds of Formula A, or a pharmaceutically acceptable salt thereof:

where A, X, R¹, and R² are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.

A method comprising: receiving, for each of a plurality of subjects, each having a specified type of cardiovascular or cardiometabolic disease and receiving at least one specified therapy from a set of therapies for treating cardiovascular and cardiometabolic diseases, a first score representing a first genetic predisposition in said subject to respond to one or more of said set of therapies; at a training stage, training a machine learning model on a training set comprising: (i) all of said first scores, and labels associated with a response in each of said subjects to said at least one specified therapy; and at an inference stage, apply said trained machine learning model to a target said first score received with respect to a target subject, to predict a response in said target subject to at least one of said therapies in said set.

The present invention relates to Compounds of Formula I: I and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treatment or prophylaxis of cardiometabolic diseases including high blood pressure, heart failure, kidney disease, and diabetes in a subject.

Systems and methods for screening whether a candidate compound inhibits delta-6 desaturase activity are disclosed. Also disclosed is a transgenic mammal which overexpresses a gene encoding delta-6 desaturase and an animal model of a cardiometabolic disorder or disease that includes the transgenic mammal. A method of treating a cardiometabolic disorder or disease is also disclosed.

Described herein are combinations useful for treating or preventing a cardiometabolic disease or disorder, or which can be used for appetite suppression, for improvement of endothelial function, for controlling weight, or a combination of one or more thereof. The combinations comprise Berberine, alpha lipoic acid (LA), and apocynin, or an isomer, derivative, pharmaceutically acceptable salt or ester of one or more thereof. Methods of treatment using the combinations, as well as compositions and re lated medical uses are also described.

The present disclosure relates to a method for measuring aggregation of low-density lipoprotein (LDL). The susceptibility of LDL to aggregate is an important factor regarding prognosis, diagnosis and surveillance of atherosclerotic cardiovascular diseases and cardiometabolic diseases, such as type 2 diabetes and related conditions, at various stages of their development. Also provided are methods of treatment of such diseases in subjects in need thereof.

The growing prevalence of obesity and type 2 diabetes complicates risk and clinical management by potentiating and/or exacerbating hypertension, hyperlipidemia, atherosclerosis and cardiomyopathy, leading to increasing use of the term “cardiometabolic disease” (CMD) to encompass the many facets of this complex syndrome. The inventors assessed the role of the soluble epoxide hydrolase (she) phosphatase domain in metabolism and cardiovascular system, by generating sEH phosphatase knock-in (KI) animals (rats). They unexpectedly revealed that inhibition of the phosphatase domain of sEH improves cardiac systolic function, decreases body weight and increases insulin sensitivity. Moreover under high fat diet, the animals have a decreased body weight gain, were protected against the development of insulin resistance, hepatic steatosis and cardiac hypertrophy. Inhibition of the phosphatase domain of sEH thus represents a new pharmacological target in the treatment of cardiometabolic diseases.

The present disclosure relates to methods of treating or preventing metabolic syndrome and/or cardiometabolic disease by administration of 15-HEPE, 15-HETrE, or compositions thereof.